Bausch + Lomb/$BLCO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Ticker
$BLCO
Sector
Primary listing
NYSE
Employees
13,000
Headquarters
Vaughan, Canada
Website
Bausch + Lomb Metrics
BasicAdvanced
$6bn
-
-$0.48
0.56
-
Price and volume
Market cap
$6bn
Beta
0.56
52-week high
$18.92
52-week low
$13.20
Average daily volume
427k
Financial strength
Current ratio
1.546
Quick ratio
0.812
Long term debt to equity
78.709
Total debt to equity
79.376
Interest coverage (TTM)
1.04%
Profitability
EBITDA (TTM)
743
Gross margin (TTM)
60.63%
Net profit margin (TTM)
-3.21%
Operating margin (TTM)
7.61%
Effective tax rate (TTM)
-150.77%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
1.50%
Return on equity (TTM)
-2.52%
Valuation
Price to revenue (TTM)
1.128
Price to book
0.93
Price to tangible book (TTM)
-3.93
Price to free cash flow (TTM)
43.849
Free cash flow yield (TTM)
2.28%
Free cash flow per share (TTM)
0.386
Growth
Revenue change (TTM)
8.85%
Earnings per share change (TTM)
-38.45%
3-year revenue growth (CAGR)
10.89%
3-year earnings per share growth (CAGR)
6.13%
Bausch + Lomb News
AllArticlesVideos
Bausch + Lomb Q2 Earnings Call Highlights
MarketBeat·3 days ago
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Business Wire·3 weeks ago
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.